Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
probiotic cocktail capsules
Hospital Authority, Hong Kong
Vancomycin-Resistant Enterococci
1 trial -
probiotics
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Necrotizing Enterocolitis
1 trial -
probiotics
Hospital Authority, Hong Kong
Parkinson's Disease (PD)
1 trial -
probiotics
The First People's Hospital of Lianyungang
Ulcerative Colitis
1 trial -
propofol
The First People's Hospital of Lianyungang
Anesthesia
1 trial -
pure give pectin 20g/d for five days
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Inflammatory Bowel Disease
1 trial -
rabeprazole plus aspirin versus rabeprazole plus clopidogrel
Hospital Authority, Hong Kong
Gastric Ulcer
1 trial -
radiochemotherapy 1
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Non Small Cell Lung Cancer
1 trial -
remimazolam
Xiyuan Hospital of China Academy of Chinese Medical Sciences
General Anesthetic Drug Adverse Reaction
1 trial -
remimazolam combined with remifentanil
The First People's Hospital of Lianyungang
Difficult or Failed Intubation
1 trial -
routine aspirin and heparin treatment
The First People's Hospital of Lianyungang
Acupuncture
1 trial -
salbutamol
The First People's Hospital of Lianyungang
Liver Transplantation
1 trial -
salvianolate injection
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Angina, Stable
1 trial -
seasonal influenza vaccine
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Influenza, Human
1 trial -
simiaowan
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Gout Flare
1 trial -
simultaneous integrated boost intensity-modulated radiation therapy combined with ripretinib
The First People's Hospital of Lianyungang
Gastrointestinal Stromal Tumors
1 trial -
sodium bicarbonate Ringer's solution
The First People's Hospital of Lianyungang
Hepatic Ischemia
1 trial -
solifenacin
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Urinary Incontinence
1 trial -
solu medrol
The First People's Hospital of Lianyungang
Immunosuppression
1 trial -
standard-of-care imaging (18F-FDG, 68Ga-PSMA, or 68Ga-DOTATATE PET/CT), 68Ga-MY6349 PET/CT
The First People's Hospital of Lianyungang
Tumor
1 trial -
standard-of-care imaging (PSMA/FDG PET/CT), ACP3 PET/CT
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Prostate Cancer (Diagnosis)
1 trial -
stereotactic body radiotherapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Prostate Cancer
1 trial -
steroid therapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Sudden Hearing Loss
1 trial -
sunitinib or pazopanib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Metastatic Renal Cell Carcinoma
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources